Success Metrics

Clinical Success Rate
25.0%

Based on 1 completed trials

Completion Rate
25%(1/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
3(60%)

Phase Distribution

Ph phase_2
2
40%
Ph phase_3
2
40%
Ph phase_4
1
20%

Phase Distribution

0

Early Stage

2

Mid Stage

3

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
2(40.0%)
Phase 3Large-scale testing
2(40.0%)
Phase 4Post-market surveillance
1(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

20.0%

1 of 5 finished

Non-Completion Rate

80.0%

4 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(1)
Terminated(4)

Detailed Status

Terminated3
Withdrawn1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
25.0%
Most Advanced
Phase 4

Trials by Phase

Phase 22 (40.0%)
Phase 32 (40.0%)
Phase 41 (20.0%)

Trials by Status

terminated360%
withdrawn120%
completed120%

Recent Activity

0 active trials
Showing 5 of 5
terminatedphase_3

A Study to Assess the Efficacy of Intravenous/Oral Bondronat (Ibandronate) in Patients With Metastatic Bone Disease Experiencing Moderate to Severe Pain

NCT00099177
withdrawnphase_2

A Study of Loading Doses of Intravenous Bondronat (Ibandronate) in Patients With Breast Cancer and Metastatic Bone Disease.

NCT00478270
terminatedphase_3

A Study to Assess the Efficacy of Intravenous Bondronat (Ibandronate) in Patients With Malignant and Painful Bone Disease

NCT00099203
terminatedphase_4

Loading Dose or Standard Dose of Intravenous Ibandronate in Treating Patients With Lung Cancer and Skeletal Metastasis

NCT00492843
completedphase_2

A Study of Loading Doses of Intravenous Bondronat (Ibandronate) in Patients With Breast Cancer and Malignant Bone Disease.

NCT00502736

Clinical Trials (5)

Showing 5 of 5 trials
NCT00099177Phase 3

A Study to Assess the Efficacy of Intravenous/Oral Bondronat (Ibandronate) in Patients With Metastatic Bone Disease Experiencing Moderate to Severe Pain

Terminated
NCT00478270Phase 2

A Study of Loading Doses of Intravenous Bondronat (Ibandronate) in Patients With Breast Cancer and Metastatic Bone Disease.

Withdrawn
NCT00099203Phase 3

A Study to Assess the Efficacy of Intravenous Bondronat (Ibandronate) in Patients With Malignant and Painful Bone Disease

Terminated
NCT00492843Phase 4

Loading Dose or Standard Dose of Intravenous Ibandronate in Treating Patients With Lung Cancer and Skeletal Metastasis

Terminated
NCT00502736Phase 2

A Study of Loading Doses of Intravenous Bondronat (Ibandronate) in Patients With Breast Cancer and Malignant Bone Disease.

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5